Literature DB >> 9055807

A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases.

P J Goadsby1, R B Lipton.   

Abstract

The short-lasting primary headache syndromes may be conveniently divided into those exhibiting marked autonomic activation and those without autonomic activation. The former group comprise chronic and episodic paroxysmal hemicrania, short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT syndrome) and cluster headache. These headache syndromes are compared with other short-lasting headache disorders, such as hypnic headache, and persistent headache with milder autonomic features such as hemicrania continua. Cluster headache is included with the shorter-lasting headaches to attempt a nosological analysis of these syndromes. The paroxysmal hemicranias are characterized by frequent short-lasting attacks of unilateral pain usually in the orbital, supraorbital or temporal region that typically last minutes. The attack frequency usually ranges from 5 to 40 attacks per day. The pain is severe and associated with autonomic symptoms such as conjunctival injection, lacrimation, nasal congestion, rhinorrhoea, ptosis or eyelid oedema. Almost all reported cases respond to treatment with indomethacin, but respond poorly to other treatments including other nonsteroidal anti-inflammatory drugs. A recent case study demonstrated the release of both trigeminal and parasympathetic neuropeptides during a bout of pain in the same pattern previously described in cluster headache. The SUNCT syndrome is a distinctive rare condition characterized by less severe pain but marked autonomic activation during attacks. Consistent with previous reports, the present case of SUNCT syndrome was intractable to therapy. The similarites of these syndromes suggests a considerable shared pathophysiology. It is suggested that the syndromes are sufficiently well established for inclusion in the International Headache Society Classification system and that trigeminal-autonomic cephalalgias should be classified as a group together. A proposed re-classification is presented.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9055807     DOI: 10.1093/brain/120.1.193

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  94 in total

1.  Hypnic headache: clinical course and treatment.

Authors:  Hans-Christoph Diener; Mark Obermann; Dagny Holle
Journal:  Curr Treat Options Neurol       Date:  2012-02       Impact factor: 3.598

2.  A revised classification of headache disorders.

Authors:  Richard Peatfield
Journal:  BMJ       Date:  2004-01-17

3.  Abstracts of the 13th Meeting of the European Neurological Society. 14-18 June 2003, Istanbul, Turkey.

Authors: 
Journal:  J Neurol       Date:  2003-05       Impact factor: 4.849

Review 4.  New daily persistent headache.

Authors:  Peter J Goadsby; Christopher Boes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

Review 5.  Trigeminal autonomic cephalgias.

Authors:  Manjit S Matharu; Peter J Goadsby
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

Review 6.  Deep brain stimulation in cluster headache: hypothalamus or midbrain tegmentum?

Authors:  Manjit S Matharu; Ludvic Zrinzo
Journal:  Curr Pain Headache Rep       Date:  2010-04

Review 7.  Traumatic head injury in cluster headache: cause or effect?

Authors:  Giorgio Lambru; Manjit Matharu
Journal:  Curr Pain Headache Rep       Date:  2012-04

8.  Paroxysmal hemicrania responding to topiramate.

Authors:  A S Cohen; P J Goadsby
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01       Impact factor: 10.154

Review 9.  Mechanism of action of indomethacin in indomethacin-responsive headaches.

Authors:  Oliver Summ; Stefan Evers
Journal:  Curr Pain Headache Rep       Date:  2013-04

10.  SUNCT and SUNA: Recognition and Treatment.

Authors:  Juan A Pareja; Mónica Alvarez; Teresa Montojo
Journal:  Curr Treat Options Neurol       Date:  2013-02       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.